{"id":"W2105518844","doi":"10.1016/j.lungcan.2010.05.022","title":"A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Bayer Canada; Eli Lilly and Company","keywords":"Medicine; Sorafenib; Carboplatin; Pemetrexed; Internal medicine; Etoposide; Oncology; Refractory (planetary science); Lung cancer; Cisplatin; Urology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002423109,0.0002617626,0.0007429075,0.0002653473,0.0000589343,0.000012597,0.0001582085,0.00008992929,0.0003721369],"category_scores_gemma":[0.000537845,0.0001758243,0.00008164778,0.0005597849,0.0002258369,0.000130144,0.0000827443,0.0006426192,0.000003024058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004564822,"about_ca_system_score_gemma":0.00127056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001454586,"about_ca_topic_score_gemma":0.006359026,"domain_scores_codex":[0.997753,0.0000515457,0.0005250528,0.000400452,0.0007913173,0.0004785803],"domain_scores_gemma":[0.9985439,0.0001784646,0.0002727447,0.0004671093,0.00034833,0.0001894598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7576725,0.008504229,0.1579575,0.001978034,0.001092131,0.0004490393,0.004007993,0.00003935354,0.05237516,0.0001167217,0.004104169,0.01170321],"study_design_scores_gemma":[0.8655909,0.02678226,0.06031398,0.002056078,0.0006023924,0.00001168199,0.0003138364,0.0008635736,0.04107364,0.00005339173,0.001640315,0.0006979245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948425,0.0002190013,0.000005265761,0.0003632604,0.0006019026,0.002312836,0.00007307219,0.00004589777,0.001536299],"genre_scores_gemma":[0.9979302,0.00007040761,0.0003404834,0.0001580428,0.0002622144,0.0005345667,0.00002832818,0.00005264842,0.0006231056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1079184,"threshold_uncertainty_score":0.7169907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01762870376819342,"score_gpt":0.3877932423721357,"score_spread":0.3701645386039423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}